Paul Anthony Stupple

This inventor holds 33 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: Pfizer Corporation, Ctxt Pty Limited, Icagen, Inc.. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Anthony Stupple. Retrieved from https://idiyas.com/inventor/paul-anthony-stupple

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 3)

% Patents Active = 51.5

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 116(Granted Patents)

Location History:

County of Kent, GB (2004)
Canterbury, GB (2005 - 2007)
Sandwich, GB (2006 - 2015)
Bundoora, AU (2016 - 2018)
Victoria, AU (2018 - 2021)
Melbourne, AU (2022)
Parkville, AU (2023)

Company Filing History:

Agouron Pharmaceuticals, Inc.

patents

5. 3 out of 7

Cancer Therapeutics Crc Pty Limited

patents

6. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

Benzisoxazole Derivatives

Pyridine Derivatives

VEGFR3 Inhibitors

Tetrahydroisoquinolines

Sulfonamide Derivatives

Pyrazole Derivatives

Imidazopyridine

Tropomyosin-Related Kinase

Aminoindane

Heteroaryl Compounds

Chemical Compounds

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12545669 - Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives (2026-02-10),

2. 11613525 - Substituted condensed thiophenes as modulators of sting (2023-03-28),

3. 11492346 - Benzisoxazole sulfonamide derivatives (2022-11-08),

4. 11028101 - 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies (2021-06-08),

5. 10961256 - PRMT5 inhibitors (2021-03-30),

6. 10947234 - PRMT5 inhibitors (2021-03-16),

7. 10787434 - Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies (2020-09-29),

8. 10745380 - Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies (2020-08-18),

9. 10550096 - Tetrahydroisoquinolines as PRMT5 inhibitors (2020-02-04),

10. 10519167 - 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies (2019-12-31),

11. 10494376 - Tetrahydroisoquinoline derived PRMT5-inhibitors (2019-12-03),

12. 10421743 - Tetrahydroisoquinolines as PRMT5 inhibitors (2019-09-24),

13. 10005792 - Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors (2018-06-26),

14. 9856252 - 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase (2018-01-02),

15. 9266864 - VEGFR3 inhibitors (2016-02-23),

Title: Paul Anthony Stupple: Innovator and Inventor in Pharmaceutical Chemistry

Introduction: Paul Anthony Stupple is a distinguished inventor based in Sandwich, GB, with an impressive portfolio of 32 patents to his name. His work primarily focuses on innovative compounds that contribute to significant advancements in the pharmaceutical industry. Stupple's inventions have the potential to impact the treatment of various medical conditions, particularly those concerning abnormal cell growth.

Latest Patents: Among Stupple's recent patents are noteworthy innovations including "Substituted condensed thiophenes as modulators of sting," which details a complex compound structure designed for modulation purposes. This patent outlines various configurations of R groups, demonstrating Stupple's intricate understanding of chemical interactions. Another recent invention, "Benzisoxazole sulfonamide derivatives," introduces novel compounds ideal for treating abnormal cell growth, such as cancer. This patent emphasizes the pharmaceutical applications of these compounds, including their potential in therapeutic compositions and treatment methodologies.

Career Highlights: Throughout his career, Paul has been associated with prestigious organizations such as Pfizer Corporation and Ctxt Pty Limited. His time at these companies has allowed him to collaborate with leading minds in the pharmaceutical field, further enhancing his expertise and influence in developing groundbreaking inventions.

Collaborations: Stupple has worked alongside talented professionals, including Michelle Ang Camerino and Charles Eric Mowbray. These collaborations have fostered an environment of innovation and creativity, contributing to the success and advancement of their mutual endeavors in research and development.

Conclusion: Paul Anthony Stupple is an exemplary figure in the realm of pharmaceutical innovations, with a robust record of patents that showcase his inventive spirit and dedication to improving medical treatment. His work continues to inspire future inventors and researchers in the ever-evolving landscape of pharmaceutical science.

Profile summary based on public USPTO records.